Last reviewed · How we verify
Placebo Respimat
Placebo Respimat is a Small molecule drug developed by Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center. It is currently FDA-approved for Control comparator in clinical trials for respiratory diseases. Also known as: (Spiriva®, Striverdi® or, Spiolto®).
Placebo Respimat is an inert formulation delivered via the Respimat inhaler device that serves as a control comparator in clinical trials.
Placebo Respimat is a placebo used in clinical trials for various conditions, including Chronic Obstructive Pulmonary Disease, Cardiovascular Disease, and Smoking, via the Respimat inhaler device. The active ingredients in Placebo Respimat are not specified, but it is a small molecule modality.
At a glance
| Generic name | Placebo Respimat |
|---|---|
| Also known as | (Spiriva®, Striverdi® or, Spiolto®) |
| Sponsor | Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center |
| Modality | Small molecule |
| Therapeutic area | Respiratory |
| Phase | FDA-approved |
Mechanism of action
As a placebo, it contains no active pharmaceutical ingredient and is used in randomized controlled trials to establish the efficacy and safety of active respiratory medications. The Respimat is a soft-mist inhaler device that delivers the formulation as a fine aerosol to the lungs, allowing for blinded comparison against active treatments in respiratory disease studies.
Approved indications
- Control comparator in clinical trials for respiratory diseases
Common side effects
Key clinical trials
- Study on BI 54903 (Inhaled Corticosteroid) Administered Twice Daily Via Respimat Inhaler in Patients With Asthma Inadequately Controlled on Medium Dose Inhaled Corticosteroid (ICS). (PHASE2)
- Pharmacodynamic and Pharmacokinetic Dose Ranging Study of Tiotropium Bromide Administered Via Respimat Device in Patients With Chronic Obstructive Pulmonary Disease (COPD) (PHASE2)
- A Randomised, Double- Blind, Placebo Controlled, Cross-over Efficacy and Safety Comparison of Tiotropium 5 µg Once Daily and Tiotropium 2.5 µg Twice Daily for Four Weeks in Patients With Moderate Persistent Asthma (PHASE2)
- Anti-inflammatory Effects of Tiotropium in Patients with Stable COPD (PHASE4)
- Dose Finding Study on BI54903 (Inhaled Corticosteroid) Administered Twice Daily Via Respimat® Inhaler in Asthmatic Patients Inadequately Controlled on Short-acting-beta-agonist (SABA) Therapy (PHASE2)
- Study on BI 54903 (Inhaled Corticosteroid) Administered Twice Daily Via Respimat Inhaler in Patients With Asthma Inadequately Controlled on Low Dose Inhaled Corticosteroid (ICS) (PHASE2)
- Regular Use Tiotropium and Tolerance to Bronchoprotection in Mild Asthma (PHASE4)
- A Study to Test the Combination of Tiotropium and Olodaterol Using the Respimat® Inhaler in People With Chronic Obstructive Pulmonary Disease (COPD) Who Have Different Abilities to Inhale (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo Respimat CI brief — competitive landscape report
- Placebo Respimat updates RSS · CI watch RSS
- Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center portfolio CI
Frequently asked questions about Placebo Respimat
What is Placebo Respimat?
How does Placebo Respimat work?
What is Placebo Respimat used for?
Who makes Placebo Respimat?
Is Placebo Respimat also known as anything else?
What development phase is Placebo Respimat in?
Related
- Manufacturer: Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center — full pipeline
- Therapeutic area: All drugs in Respiratory
- Indication: Drugs for Control comparator in clinical trials for respiratory diseases
- Also known as: (Spiriva®, Striverdi® or, Spiolto®)
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing